TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial fo… Read more
TWi Biotechnology, Inc. (6610) - Total Assets
Latest total assets as of June 2025: NT$393.58 Million TWD
Based on the latest financial reports, TWi Biotechnology, Inc. (6610) holds total assets worth NT$393.58 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TWi Biotechnology, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how TWi Biotechnology, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TWi Biotechnology, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TWi Biotechnology, Inc.'s total assets of NT$393.58 Million consist of 73.5% current assets and 26.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 52.3% |
| Accounts Receivable | NT$889.00K | 0.4% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$33.25 Million | 13.7% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how TWi Biotechnology, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TWi Biotechnology, Inc.'s current assets represent 73.5% of total assets in 2024, a decrease from 77.3% in 2019.
- Cash Position: Cash and equivalents constituted 52.3% of total assets in 2024, up from 13.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 13.7% of total assets.
TWi Biotechnology, Inc. Competitors by Total Assets
Key competitors of TWi Biotechnology, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TWi Biotechnology, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TWi Biotechnology, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TWi Biotechnology, Inc. is currently not profitable relative to its asset base.
TWi Biotechnology, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.78 | 4.71 | 6.02 |
| Quick Ratio | 2.78 | 4.71 | 5.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$214.34 Million | NT$ 182.58 Million | NT$ 228.67 Million |
TWi Biotechnology, Inc. - Advanced Valuation Insights
This section examines the relationship between TWi Biotechnology, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.72 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -38.9% |
| Total Assets | NT$242.32 Million |
| Market Capitalization | $26.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values TWi Biotechnology, Inc.'s assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TWi Biotechnology, Inc.'s assets decreased by 38.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TWi Biotechnology, Inc. (2019–2024)
The table below shows the annual total assets of TWi Biotechnology, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$242.32 Million | -38.94% |
| 2023-12-31 | NT$396.85 Million | +69.37% |
| 2022-12-31 | NT$234.31 Million | -24.67% |
| 2021-12-31 | NT$311.04 Million | -19.64% |
| 2020-12-31 | NT$387.04 Million | -9.80% |
| 2019-12-31 | NT$429.10 Million | -- |